Journal of Clinical Oncology
Articles in this Issue
The landscape of MET alterations in non-small cell lung cancer in Southeast China: A real-world study.
e20686 Background: MET alterations are critical oncogenic drivers in NSCLC. However, real-world data regarding the distrib...
Tracking genomic evolution in <i>ERBB2</i> -altered biliary tract cancer through longitudinal tumor profiling.
4137 Background: HER2, encoded by ERBB2 (HER2), is overexpressed and clinically ac...
Real world outcomes of neoadjuvant immune checkpoint blockade (ICB) for resectable stage III melanoma: Pathologic response and FDG PET/CT correlates.
9569 Background: Neoadjuvant (NA) ICB is standard of care for resectable stage III melanoma, with major pathological (p) r...
Safety and efficacy of nesuparib (JPI-547) with gemcitabine-nab-paclitaxel (GemAbraxane) or modified FOLFIRINOX (mFOLFIRINOX) in patients with locally advanced or metastatic PDAC: Results from an ongoing phase Ib/II study.
4193 Background: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies with poor outcomes in...
Clinical outcomes of heart failure in breast cancer patients receiving HER2-directed therapy: A retrospective analysis (2016–2020).
e13003 Background: HER2-directed therapies are a used in the treatment for HER2-positive breast cancer but are associated...
Evaluation of survival after induction immunochemotherapy followed by concurrent chemoradiotherapy in unresectable esophageal cancer: A systematic review, meta-analysis, and network meta-analysis.
e16137 Background: Concurrent chemoradiotherapy (CCRT) remains the standard treatment for nonsurgical esophageal cancer (E...
Reirradiation with NBTXR3/SBRT in combination with nivolumab or pembrolizumab for the treatment of patients with recurrent or metastatic head & neck squamous cell carcinoma (HNSCC) in the phase I trial study 1100.
6034 Background: HNSCC reirradiation with stereotactic body radiation therapy (SBRT) has emerged as a potential option for...
From trials to the clinic: Real-world experience with mirvetuximab soravtansine in platinum-resistant ovarian cancer and the "Lazarus effect.
e17579 Background: Platinum-resistant ovarian cancer (PROC) has limited treatment options, with response rates of 10–15% a...
Feasibility and preliminary efficacy of a peer community navigator (PCN)–led intervention for minoritized individuals considering early-phase clinical trials (EPCTs).
e23152 Background: EPCTs assess the safety and early clinical activity of new cancer therapies. Underrepresentation of mem...
Impact of COVID-19 pandemic on breast cancer incidence and immunohistochemical subtype distribution: A 10-year retrospective analysis from a regional Irish cancer center.
e12584 Background: The COVID-19 pandemic disrupted cancer diagnostic pathways and screening programmes. The long-term impa...
GLP-1 receptor agonist therapy and risk of small intestinal neoplasms: Real-world evidence from a global network.
e16499 Background: As indications for GLP-1 RAs expand, their long-term oncologic safety remains a key concern. Supraphysi...
Implementation of an expedited cancer workup clinic for uninsured patients at a metropolitan safety net hospital.
1573 Background: Timely evaluation of patients with suspected cancer is essential; yet delays in diagnosis and treatment r...
Demographics and outcomes of individuals with young-onset small cell lung cancer.
8104 Background: A diagnosis of lung cancer before the age of 50 is commonly driven by oncogenic alterations and observed...
Merkel cell carcinoma incidence, trends, and survival rates among adults from United States cancer statistics during 2000-2022.
e21560 Background: Merkel cell carcinoma (MCC) is a rare form of skin cancer that frequently metastasizes and is associate...
Efficacy outcomes by patterns of progression in patients with advanced renal cell carcinoma from the phase 3 CLEAR trial.
4527 Background: In CLEAR, lenvatinib + pembrolizumab (L+P) significantly improved efficacy vs sunitinib (S) in treatment-...
Real-world chemotherapy decision pathways and survival in early HR+/HER2- breast cancer: Oncotype DX recurrence score–guided versus clinician-guided treatment in NCDB (2010–2022).
e12754 Background: Despite widespread adoption of the 21-gene Recurrence Score (Oncotype DX RS) to guide adjuvant chemothe...
Oncology social work outreach as a predictor of oncology appointment completion among cancer patients with transportation needs.
e13525 Background: Cancer patients typically have multiple treatment and evaluation appointments throughout their cancer t...
Upfront ultrafast multigene panel testing for NCCN guideline–recommended biomarker detection in advanced NSCLC.
e15094 Background: NCCN Guidelines for advanced non–small cell lung cancer (NSCLC) recommend comprehensive biomarker asses...
Evaluation of intravenous IPI201 in combination with anti–PD-1 therapy in a colorectal cancer mouse model.
2625 Background: Immune checkpoint inhibitors targeting PD-1 improve outcomes in colorectal cancer (CRC) but are limited b...
Utilisation of the Henry score in malignant bowel obstruction and characterisation of management approaches and outcomes: Experience from a New Zealand regional centre.
12049 Background: Malignant Bowel Obstruction (MBO) is a common, life-threatening complication of advanced malignancy asso...
The 2026 primary care oncology toolkit: An evolving shared-care framework for the implementation of prospective survivorship evidence.
11076 Background: As cancer survivorship transitions into a chronic disease model, a significant "implementation gap" exis...
Effects of tai chi qigong on gene expression profiles in older male cancer survivors with fatigue.
12038 Background: The HERO trial showed that Tai Chi Qigong (TCQ) reduced fatigue (primary endpoint) in male cancer surviv...
Trends in frontline treatment patterns for multiple myeloma among US veterans, 1999–2025.
7576 Background: Frontline treatment for multiple myeloma (MM) has evolved substantially, transitioning from alkylating th...
Advancing HER2 testing and evidence-based treatment in non–small cell lung cancer: A quality improvement initiative across academic and community settings.
e23309 Background: Treatment recommendations for biomarker-directed therapy in advanced non-small cell lung cancer (NSCLC)...
Impact of reflexive next-generation sequencing on treatment initiation in non–small cell lung cancer.
e20096 Background: Timely identification of actionable mutations is critical for guiding targeted therapy and immunotherap...